Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8% ...Middle East

JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a...

Hence then, the article about qilu pharmaceutical announces results from phase ii study for iparomlimab for advanced solid tumors at esmo asia with an orr of 45 8 was published today ( Wednesday 06/12/2023 - 11:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8% )

Also on site :

• Primary school teacher banned after drinking can of beer in classroom and eating mints after every sip
• Greenland warns of ‘red lines’ in talks with US
• A New Lawsuit Is Taking Aim at Costco’s Beloved $4.99 Rotisserie Chicken